Member Info for liquid1

Ncyt mcap 109m

If we get to 109m cap in 8 weeks sp will be 12 x higher than now.......or 300p!

Genedrive (LON:GDR) Rating Reiterated by Peel Hunt
Wednesday, March 25th, 2020
Mini Blandt

Genedrive (LON:GDR)‘s stock had its “buy” rating reaffirmed by analysts at Peel Hunt in a note issued to investors on Wednesday, ThisIsMoney.Co.Uk reports.

https://www.google.co.uk/amp/s/redmondregister.com/2020/03/25/genedrive-longdr-rating-reiterated-by-peel-hunt.html/amp

Broker Forecast - Peel Hunt issues a broker note on Genedrive Plc
29 March 2019, 08:10Source - SMW
Peel Hunt today reaffirms its buy investment rating on Genedrive Plc (LON:GDR) and set its price target at 60p.

Broker Forecasts data provided by www.sharesmagazine.co.uk

https://www.sharesmagazine.co.uk/news/market/6366873/Broker-Forecast-Peel-Hunt-issues-a-broker-note-on-Genedrive-Plc

Mcap far too low

Asking for 39p now!

In a trading update, the diagnostics firm said following discussions with suppliers it believed it could “quickly” ramp up production of its 96 SARS-COV-2 test, which can determine whether someone is infected with coronavirus, to over 10,000 tests per hour, making the product “a material revenue generator for the company and significant contributor to addressing the global pandemic”.

As the test is freeze dried, it requires no refrigeration and is easier to transport, which the company said provides it with a “significant logistical advantage for rapid shipment and global distribution”.

Genedrive is also developing a second SARS-COV-2 test which it says will allow testing outside of a hospital environment in places such as clinics and intensive care units where rapid results are required.

Shares outstanding 34.87m
Free float 12.12m

https://markets.ft.com/data/equities/tearsheet/summary?s=GDR:LSE

How to Buy
UK customers
For pricing, sales or training enquiries relating to the TrueVue monitors, probes and accessories, please contact Customer Services directly on 01243 774 837 or email Customer Services directly.

(Office hours are Monday – Friday 8.30 – 5.00).

Placing orders
Orders can be emailed directly to customer.services@deltexmedical.com or faxed to 01243 532 534
Additionally, both monitors and probes can be ordered directly via The NHS Supply Chain quoting the National Framework Reference: 2011/S165-272795.
To find your local sales or product specialist, please email uksales@deltexmedical.com and we will respond as quickly as possible.

USA customers
For any pricing, sales or training enquiries relating to the CardioQ-EDM+ monitor, probes and accessories, please contact the Corporate Office directly; 864 527 5913 or email ussales@deltexmedical.com

Placing orders
Orders can be faxed direct using the dedicated fax line: 864 527 5914

https://www.deltexmedical.com/contact-us/how-to-buy/

Away from the blue-chips, Deltex Medical Group plc (LON:DEMG), the blood-flow monitoring company, was the best performer, up 94% at 1.75p, albeit on zero news flow.

The oesophageal Doppler monitoring technology company has had trouble getting its foot in the door in the past at the National Health Service but perhaps the current crisis could lead to a change of heart (monitoring).

https://www.proactiveinvestors.co.uk/companies/news/915601/ftse-100-advances-over-9-as-markets-bounce-back-amid-us-government-stimulus-hopes-915601.html

From Advfn: DEMG's Doppler technology

Will have a go: it all gets very techy quite quickly, but, basically, you do want a ventilator if in crisis with CoVid and, when on a ventilator, you really want to be on a cardiac output monitor

CoVid 19 causes inflammatory responses which can trigger many different further problems. Part of the management of inflammation is to use fluids to optimise oxygen delivery around the body at times of crisis: effectively trying to minimise the internal swelling

DEMG's Doppler technology is the best available to do this because it actually measures in real time the blood being pumped by the heart (see graphic on their homepage) and has very few confounders

LID have also had a good bump in SP this week. Their tech is also useful even if derived from peripheral blood pressures. Its strength comes from measuring pulse pressure variation which is well validated in ventilated patients so long as certain settings are at certain levels and the patient is 100% mechanically ventilated (i.e. no spontaneous breathing)

DEMG's monitors allow the same as LID's as well as Doppler so are perfect for both the sickest and the recovering patients. Some DEMG boxes also have the bio-impedance technology

So, with all the noise around urgent NHS need for ventilators, it looks like the market is working out that, once ventilated, the patients also need high end cardiac output monitoring and DEMG has the highest end 'flow' offer as well as the more standard 'pressure' one

Will have a go: it all gets very techy quite quickly, but, basically, you do want a ventilator if in crisis with CoVid and, when on a ventilator, you really want to be on a cardiac output monitor

CoVid 19 causes inflammatory responses which can trigger many different further problems. Part of the management of inflammation is to use fluids to optimise oxygen delivery around the body at times of crisis: effectively trying to minimise the internal swelling

DEMG's Doppler technology is the best available to do this because it actually measures in real time the blood being pumped by the heart (see graphic on their homepage) and has very few confounders

LID have also had a good bump in SP this week. Their tech is also useful even if derived from peripheral blood pressures. Its strength comes from measuring pulse pressure variation which is well validated in ventilated patients so long as certain settings are at certain levels and the patient is 100% mechanically ventilated (i.e. no spontaneous breathing)

DEMG's monitors allow the same as LID's as well as Doppler so are perfect for both the sickest and the recovering patients. Some DEMG boxes also have the bio-impedance technology

So, with all the noise around urgent NHS need for ventilators, it looks like the market is working out that, once ventilated, the patients also need high end cardiac output monitoring and DEMG has the highest end 'flow' offer as well as the more standard 'pressure' one

Shares outstanding 524.46m
Free float 142.91m

https://markets.ft.com/data/equities/tearsheet/summary?s=DEMG:LSE

News on their website!

Response to Covid 19

We fully appreciate that the NHS is facing an unprecedented disruption to the normal running of business over the coming months and many hospitals have requested that all non-essential supplier visits to the Trust are suspended.

At Deltex Medical we are, as always, here to help where we can and will provide free access to haemodynamic monitoring for those patients that may require it within your ICU. We have manufactured additional monitors and probes to ensure that we can cope with the additional demand and will provide monitors on loan on a free of charge basis to those hospitals that require them.

We will endeavour to fulfil all requests for monitors and probes within 48 hours, assuming we do not need to close our offices. Should the office be forced to close for any period of time, your local representatives will carry an emergency supply and can arrange local delivery. Our staff are all familiar with ITU practises and protocols and are available to support and train when and where they are needed and within all current guidelines. We also have free access to online clinical training and education to reduce face to face meetings.

www.deltexmedical.com/education/en/

Please do not hesitate to request our help if required at info@deltexmedical.com

https://www.deltexmedical.com/

Only 3 MM’s control this, the 4th MM is sleeping at 12p.

He or she needs awakening!

Market cap only 6.8million

THE SOLUTION
Salarius patented1 technology is able to achieve the same saltiness of traditional salt with half of the sodium, by reducing the size of regular salt particles thereby increasing the surface area that is touching the tongue. Due to the size of the nano-particles, it dissolves virtually immediately, delivering a higher sense of saltiness with less salt. MicroSalt® has less sodium per unit volume than an equivalent unit volume of traditional sodium chloride.

MicroSalt® is perfect for dry topical applications like chips, tortilla chips, nuts, crackers, popcorn and many other snacks. The Salarius MicroSalt® tastes exactly like salt because it is salt.

THE PROBLEM
Salt is the primary sodium ingredient used in processed food, and makes the greatest contribution to sodium intake in the United States. Too much sodium can raise blood pressure, which is a major risk factor for heart disease and stroke. As much as 70% of the average American’s salt intake comes from processed and restaurant foods, not salt added at the table.

Americans consume an average of 3,400mg of sodium per day – 50% more than the 2,300mg voluntary limit recommended by federal guidelines. Consequently, 1 in 3 US adults (70M) have high blood pressure and in the U.K., I in 4 adults have high blood pressure.

According to the FDA, reducing sodium intake by 33% will reduce an estimate of 28,000 to 50,000 premature deaths per year.

24 March 2020

Tekcapital Plc

("Tekcapital", the "Company" or "the Group")

Portfolio Company Update

Salarius confirms 71 store roll out for SaltMe!(R) sncks in May 2020

Tekcapital Plc (AIM: TEK), the UK intellectual property investment group focused on creating marketplace value from investing in university technology, is very pleased to announce that portfolio company Salarius ltd., ("Salarius") has received an order from its distribution partner to launch sales of its new SaltMe!(R) full flavour-low sodium snacks in 71 stores in May 2020.

This action represents an important milestone for SaltMe!(R) new low-sodium, full flavor potato crisp snack line, because thousands of customers will be able to rapidly find and buy the new chips.

"We are very excited to execute this program that will put this new and fantastic brand in front of thousands of consumers quickly. In a world where taste is everything, we feel optimistic that SaltMe!(R) snacks will engender strong loyalty and repurchase from our new customers." says Victor Hugo Manzanilla, CEO of Salarius.

The highly competitive global savory snacks market is expected to reach US$108 billion by 2021. SaltMe! Snacks with MicroSalt(R) is a better-for-you snack food whose time has come.

Commenting on the patenting activities, Bob Rauker, CEO of Belluscura, said: "We are very excited about our next generation oxygen technologies. With the launch this year of our first product, the X-PLOR™ portable oxygen concentrator, into the respiratory treatment field where over 250 million people suffer from chronic obstructive pulmonary disease (COPD), the third leading cause of death, it is critical that we continue to innovate into the ever-expanding oxygen therapy market."

Tekcapital plc
Belluscura likely to receive FDA clearance in 2019
RNS Number : 4150D
Tekcapital plc
26 June 2019


26 June 2019

Tekcapital Plc

("Tekcapital", the "Company" or "the Group")

https://www.investegate.co.uk/tekcapital-plc--tek-/rns/belluscura-likely-to-receive-fda-clearance-in-2019/201906260700064150D/

Portfolio Company Update: Belluscura plc

On track to likely receive FDA clearance later this year